Related Experiment Videos
[Gamma-vinyl-GABA: first experiences in Italy. II]
1Dipartimento di Scienze Neurologiche, Università degli Studi di Roma La Sapienza.
La Clinica Terapeutica
|March 1, 1994
Summary
Gamma-vinyl-GABA (GVG) showed initial effectiveness but lost efficacy over time in drug-resistant epilepsy patients. GVG is currently a safe and effective option for initial monotherapy in epilepsy treatment.
Area of Science:
- Neurology
- Pharmacology
Background:
- Epilepsy management requires effective antiepileptic drugs.
- Drug resistance is a significant challenge in epilepsy treatment.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of gamma-vinyl-GABA (GVG) in patients with drug-resistant epilepsy.
- To assess GVG's effectiveness as monotherapy and add-on therapy.
Main Methods:
- Patients with drug-resistant cerebral प्याज (CPC) and CPC with secondarily generalized seizures were studied.
- GVG was administered initially as monotherapy, followed by add-on therapy with carbamazepine, phenobarbital, or valproate.
Main Results:
- A loss of efficacy of GVG was observed during long-term treatment.
- GVG demonstrated safety and effectiveness as an initial monotherapy for epilepsy.
Conclusions:
- Long-term use of GVG may lead to a diminished therapeutic effect.
- GVG is a viable and safe choice for the initial management of epilepsy.